

The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.

Bonnie Bruce and James F Fries

J Rheumatol 2003;30:167-178

<http://www.jrheum.org/content/30/1/167>

1. Sign up for our monthly e-table of contents  
<http://www.jrheum.org/cgi/alerts/etoc>
2. Information on Subscriptions  
<http://jrheum.com/subscribe.html>
3. Have us contact your library about access options  
[Refer\\_your\\_library@jrheum.com](mailto:Refer_your_library@jrheum.com)
4. Information on permissions/orders of reprints  
<http://jrheum.com/reprints.html>

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

# The Stanford Health Assessment Questionnaire: A Review of Its History, Issues, Progress, and Documentation

BONNIE BRUCE and JAMES F. FRIES

**ABSTRACT.** Over the last 2 decades, assessment of patient health status has undergone a dramatic paradigm shift, evolving from a predominant reliance on biochemical and physical measurements to an emphasis upon health outcomes based on the patient's personal appreciation of their illness. The Health Assessment Questionnaire (HAQ), published in 1980, was among the first instruments based on patient centered dimensions. The HAQ was designed to represent a model of patient oriented outcome assessment and has played a major role in diverse areas such as prediction of successful aging, inversion of the therapeutic pyramid in rheumatoid arthritis (RA), quantification of nonsteroidal antiinflammatory drug gastropathy, development of risk factor models for osteoarthritis, and examination of mortality risks in RA. The HAQ has established itself as a valuable, effective, and sensitive tool for measurement of health status. It has increased the credibility and use of validated self-report measurement techniques as a quantifiable set of hard data endpoints and has contributed to a new appreciation of outcome assessment. We review the development, content, and dissemination of the HAQ and provide reference sources for its uses, translations, and validations. We discuss contemporary issues regarding outcome assessment instruments relative to the HAQ's identity and utility. These include: (1) the issue of labeling instruments as generic versus disease-specific; (2) floor and ceiling effects in scales such as "disability"; (3) distances between values on scales; and (4) the continuing introduction of new measurement instruments and their potential effects. (J Rheumatol 2003;30:167-78)

*Key Indexing Terms:*

STANFORD HEALTH ASSESSMENT QUESTIONNAIRE      HAQ      DISABILITY INDEX

The impact of chronic illness is a function of illness severity, the individual patient, and time. Further, it is affected by factors such as age, sex, lifestyle, motivation, priorities, and aspirations. Over the past 2 decades, assessment of patient health status has undergone a dramatic paradigm shift, evolving from a predominant reliance on biochemical and physical measurements, such as erythrocyte sedimentation rate, lipid profiles, or radiographs, to an emphasis upon health outcomes based on the patient's personal assessment of their health status. The shift to inclusion of patient centered values permits longterm, cumulative assessment of outcomes that are relevant to the patient.

The Health Assessment Questionnaire (HAQ) has played an influential role in constructing this new paradigm and in establishing health outcome assessment as a quantifiable set of hard data endpoints that are reliable, valid, and sensitive to

change. Its intellectual roots included work by Donabedian<sup>1</sup>, Katz<sup>2</sup>, Steinbrocker<sup>3</sup>, Convery<sup>4</sup>, and others. This is a review of the HAQ; it is not a review of outcome assessment or a comparison of the HAQ with other instruments. It describes the HAQ in detail, provides an overview of a substantial part of the HAQ literature, and discusses our view of associated issues. We also provide references for relevant HAQ publications<sup>1-183</sup> since the last review by Ramey and Fries in 1996<sup>135</sup> and information to access translations and adaptations. The HAQ instrument, scoring directions, and additional resources may be accessed at the ARAMIS website, <http://aramis.stanford.edu>.

## UNDERLYING PRINCIPLES OF THE HAQ

*Dimensions of health outcomes.* What are health outcomes? Why are they important? Are they best based on physician, societal, or patient values? We have argued that these 3 value systems should converge with a service oriented medical profession and a benevolent society, but that the patient's values in particular must be preserved and protected. Studies of patient centered health values have tended to yield 5 generic outcome dimensions, the "5 D's." When queried, patients report that they want: (1) to postpone death, (2) to avoid disability, (3) to be free of pain and discomfort, (4) to avoid

*From the Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.*

*Supported by grant AR43584 from the National Institutes of Health (NIH) to the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS).*

*B. Bruce, DrPH, Research Associate; J.F. Fries, MD, Professor of Medicine.*

*Address reprint requests to Dr. B. Bruce, Suite 203, 1000 Welch Road, Palo Alto, CA 94304. E-mail: [bbruce@Stanford.edu](mailto:bbruce@Stanford.edu)*

adverse effects of treatment, such as drug side effects, and (5) to keep dollar costs of treatment low<sup>54,60,104,130</sup>. As an aggregate, they define health outcome in patient terms and can be partitioned into the 5 dimensions along with subcomponents to form a hierarchy.

On the apex of this hierarchy is the global entity of health outcome, which is a function of the underlying 5 patient centered dimensions (death, disability, discomfort, drug toxicity, and dollar costs). However, it is not possible to compute a value for health outcome directly from scores on the 5 dimensions without assuming idiomatic patient tradeoffs. For example, how many dollars saved would a patient consider that his or her life is worth? How much pain would a patient endure for how much disability? To operationalize a health dimension, there are lesser assumptions that must be made by “rolling up” values from lower in the hierarchy (e.g., Is disability in walking more or less important than disability in dressing?), but these may seem to be more defensible assumptions than dimensional death/disability or disability/side effect tradeoffs. For these reasons, we have argued for collection of data for each dimension, but have discouraged further aggregation.

These 5 dimensions of health outcome can be further subdivided into more discrete components that appear lower in this hierarchy and help to provide substance. For example, the measurement of disability can include activities that involve upper extremities, lower extremities, or both. Discomfort may include physical and/or psychological origins. Drug side effects or toxicity may encompass consequences of medical treatment or surgery. Dollar costs, or economic impact, can comprise direct (actual expenses) and indirect (loss of productivity) costs. The fact of death includes specific notation of time to death and cause of death. These components are themselves calculable from specific questions at a lower level. Hence, this hierarchical model creates a structure for the macrocosm of measures relevant to outcome and those that are indispensable for comprehensive patient assessment.

An abbreviated alternative to using the 5 dimensions in a hierarchical structure to capture health status is to employ a single global outcome question that can be asked directly using an analog scale, although, of course, with loss of precision and sensitivity to change. Such a question captures, in part, the patient’s tradeoffs between the different outcome dimensions and is also a broader perspective that may include idiomatic values such as spirituality, disability-friendly environments, and family support. Instruments that use a single-item global health visual analog scale (VAS) have been recommended as representing meaningful outcomes and internationally as one of the 6 core outcomes (i.e., disability, pain, patient global, physician global, swollen joint count, and tender joint count) to be measured in clinical studies of rheumatoid arthritis (RA)<sup>18,46,121</sup>. The HAQ and other instruments<sup>65,95,111</sup> contain such a scale.

*Longitudinal data collection.* Just as collection of patient centered data is a requisite for proper assessment of health out-

comes, cumulative effects of a patient’s chronic illness collected over time must also be considered. For evaluation of health outcome, aggregated measures captured longitudinally are superior to cross sectional assessments, since they capture the entire effect of a longterm illness and are a sensitive indicator of treatment effect over time<sup>58</sup>. Cross sectional data provide only a vertical slice of the patient’s experience at a particular point in time. For example, patient outcomes estimated solely from cross sectional measurements are unable to distinguish early development of disability from late, since cumulative disability in a patient may be vastly different than disability experienced between only 2 discrete assessment periods. Thus, reliance on a patient’s final measurement or on a first and last value may provide a biased view of the disease or treatment impact. Sequential health status measurements obtained at regular intervals permit comparison of the impact by allowing approximation of the area under the curve<sup>169</sup>. Longitudinal data should be an inherent component of patient outcome measurement assessment. A single point in time assesses health status at that point; a series of assessments permit cumulative outcome assessment.

*A psychometrically sound instrument.* Assessment of health outcomes requires an instrument with excellent psychometric properties of reliability, validity, and sensitivity<sup>70</sup>. Reliability, the ability of an instrument to produce results repeatedly, is affected by factors such as clarity and precision of language. Validity is established by assessing the degree to which the instrument measures what it is intended to measure. Sensitivity identifies the degree of an instrument’s ability to detect change over time. Measuring sensitivity to change requires graded responses (e.g., not walk versus can’t walk) and indices that have a continuous or nearly continuous scale. From these basic principles (a focus on patient centered values, use of a multidimensional instrument with established psychometric properties, and the aim of collecting data longitudinally), the HAQ was intended to assess patient outcome both comprehensively and cumulatively.

#### THE “FULL” AND “SHORT” OR 2-PAGE VERSIONS OF THE HAQ

The HAQ has been one of the most cited and employed instruments, particularly but not exclusively in the rheumatic disease literature. However, there has been some confusion relative to what the term “HAQ” refers: typically, it is used to refer to one of 2 versions of the HAQ. The full HAQ assesses 5 dimensions of health outcome (Table 1), while the version that has received the widest attention and most frequent use, and that is commonly referred to in the literature as “the HAQ,” is the “short” or 2-page HAQ. The short HAQ contains the HAQ Disability Index (HAQ-DI), the VAS Pain Scale, and the VAS Patient Global in a 2-page format, permitting convenient assessment of 3 of the 6 American College of Rheumatology (ACR) outcome measures for RA<sup>44</sup>. Further, the HAQ-DI is often used by itself.

Table 1. Structural dimensions of the 2-page or Short HAQ (Items 1 and 2) and the Full HAQ (Items 1–5).

1. Disability; these 8 categories make up the “Disability Index” (HAQ-DI):		
Dressing	Walking	
Arising	Reach	
Eating	Grip	
Hygiene	Outside activity	
2. Discomfort		
HAQ VAS pain scale	Patient Global VAS	
Supplemental dimensions also included in the Full HAQ (tailored to specific hypotheses or research questions)		
3. Drug side effects		
Medical	Toxicity Index	Surgical
4. Dollar costs		
Direct costs: Medical/surgical costs		
Medications	Paramedical visits	
Laboratory tests	Devices	
Radiographs	Hospitalizations	
Physician visits	Surgeries	
Indirect costs: Loss of productivity		
5. Death		
Time to death		
Cause of death		

The full HAQ was developed originally for use in multiple illnesses so that the effects of different disease processes could be compared, even though much of its early work emanated from the rheumatology field. For example, in osteoarthritis (OA), pain is dominant and typically increases over the years; in RA, disability is dominant, in HIV-AIDS both of these may predominate, but in almost all diseases, patients will be affected by personal issues involving the 5 patient centered dimensions. These generic objectives drove the design and development of the HAQ. As such, the full HAQ includes sections on drug side effects and medical costs, as well as supplemental sections on demographics, lifestyle, and health behaviors. As with any instrument, the HAQ has limitations, and as generally used, does not capture disability associated with sensory organ dysfunction or psychiatric dysfunction and does not directly measure patient satisfaction or social networking. Yet these variables, or other variables of interest to the user, can be readily appended as separate instruments.

The full HAQ was one of the first instruments deliberately designed to capture prospectively and by protocol the longterm influence of chronic illness. It was immediately adopted in 1980 by the Arthritis, Rheumatism, and Aging Medical Information System. It was designed to be efficient, structured for practical application during clinic visits, and to be compatible with high return rates when administered by mail or telephone. In its early development, the full HAQ was titled the “Arthritis Assessment Questionnaire” or “AAQ.” However, after it was recognized that the 5 outcome dimensions (disability, discomfort, drug toxicity, dollar costs, and death) conceptualized in the HAQ represented general con-

cepts, and were not restricted to any single specific disease area, the current HAQ name was adopted.

Both the short HAQ and the full HAQ are copyrighted for the purpose of insuring that it will be used unmodified to preserve the validity of its results and contribute to standardization of assessment across studies. However, the HAQ is considered to be in the public domain, and permission for its use is given routinely without charge. A “HAQ-PAK” containing the full HAQ and scoring directions is available on the internet at <http://aramis.stanford.edu>. Changes may sometimes be made by vendors to maintain language or cultural adaptations.

Use of the HAQ has spanned multiple and diverse settings. The full HAQ has been used by ARAMIS more than 100,000 times to assess clinical status, evaluate effectiveness in clinical and observational trials, and to define health outcomes<sup>56</sup>. Studies using the HAQ have been conducted in patients with HIV-AIDS, normal aging populations, adults and children with rheumatic diseases, and in disabled workers<sup>26,56,57,106,135</sup>. It has been employed in population based studies, including the followup to the National Health and Nutrition Examination Survey (NHANES)<sup>86</sup>. It has been applied to a variety of diseases and conditions, including OA, juvenile RA, systemic lupus erythematosus, ankylosing spondylitis, fibromyalgia, psoriatic arthritis, and systemic sclerosis. Extensively implemented internationally, the HAQ-DI has been translated and culturally validated into more than 60 languages (Table 2).

The components of the “short” HAQ have retained their original content and format since the early 1980s, while the additional dimensions in the full HAQ, drug side effects and dollar costs and other items, are periodically tailored and supplemented with additional questions when contemporary issues arise for specific hypotheses or research questions by ARAMIS or other investigators. The dimension of mortality is assessed by specific ARAMIS protocols.

#### DEVELOPMENT OF THE HAQ-DI

The HAQ-DI, initially developed in the late 1970s under the auspices of the Stanford Arthritis Center, was the original HAQ section to be developed and validated. The HAQ-DI was developed by parsing questions and components from a variety of instruments<sup>59</sup>. It recognized the importance of the original American Rheumatism Association (ARA) functional class measure<sup>3</sup> and also the lack of sensitivity to change of that 4 category measure. It evolved over numerous iterations through a series of subjective and objective assessments via statistical evaluation, physician appraisal, and patient feedback<sup>58,59</sup>. Associations with clinical variables such as sedimentation rate or tender joint counts were tested, where we sought to achieve equal or better measurement characteristics with more patient outcome related dependent variables.

A comprehensive validation of each item set was performed to yield the final instrument. Correlation matrices were constructed, and intercorrelations, item-total correla-

tions, correlations with extant “gold standards” such as performance of activities of daily living, physiological and biochemical measures, and chart reviews were evaluated. When 2 items had correlations of  $\geq 0.90$ , indicating redundancy, one was eliminated, as were items with correlations of  $\leq 0.50$  since such items did not accurately measure the dimension represented by the other items in the index or had ambiguous, inconsistent, or incomplete responses. Details of HAQ development are described in Fries, *et al* (1980)<sup>58</sup> and Fries, *et al* (1982)<sup>59</sup>.

### RELIABILITY AND VALIDITY OF THE HAQ-DI

The HAQ-DI has been repeatedly validated as a reliable measurement instrument for self-assessment by mail, in the office, by telephone, and by comparison with paraprofessional and physician judgments<sup>58</sup>. Evaluations of the psychometric properties of the HAQ-DI have provided consistent and substantial evidence of both its reliability and validity across many applications and in different patient populations and are reported in detail with related publications in the 1996 HAQ review by Ramey and Fries<sup>135</sup>. The HAQ has since become one of the most frequently used instruments for evaluation of functional status, one of the instruments recommended for use in clinical trials in RA<sup>46</sup>, and has de facto become a required dependent variable for trials in RA.

Test-retest correlations confirming reproducibility have ranged from 0.87 to 0.99, and correlations between interview and questionnaire formats have ranged from 0.85 to 0.95. Validity has been confirmed in numerous studies. There is consensus that the HAQ-DI possesses face and content validity, and correlations between questionnaire or interview scores and task performance have ranged from 0.71 to 0.95, indicating criterion validity. The construct/convergent validity, predictive validity, and sensitivity to change have also been established in numerous observational studies and clinical trials<sup>135</sup>. Recently, it was compared with the Western Ontario-McMaster Universities OA Index (WOMAC) and was found to be similarly and significantly correlated (HAQ R = 0.67,  $p < 0.0001$ )<sup>136</sup>, and when compared with the modified HAQ (MHAQ) and the RA-HAQ (both shortened versions of the HAQ-DI), it was found to be more efficient at detecting change and assessing functional ability than either of the 2 comparators<sup>180</sup>.

### OVERVIEW: THE FULL HAQ

**1. Disability.** The disability assessment component of the full HAQ, the HAQ-DI, assesses a patient’s level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. It can be self-administered in 5 minutes and scored in less than one minute. Standard scoring takes into account use of aids and devices or assistance from another person. There are 20 questions in 8 categories of functioning that represent a compre-

hensive set of functional activities — dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each item asks over the past week “Are you able to...” perform a particular task. Each category contains at least 2 specific component questions. For example, under the category of arising, the patient is asked about their ability to stand up from a straight chair and to get in and out of bed.

Scoring is patterned after the ARA/ACR functional class<sup>3,80</sup>. For each item, there is a 4 level difficulty scale that is scored from zero to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. A complementary scoring method ignores scores for aids and devices when computing the category scores and represents residual disability after compensatory efforts. The 8 category scores are averaged into an overall HAQ-DI score on a scale from zero to 3, zero indicating no disability, 3 indicating complete disability. The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 ... 3). The HAQ-DI score is not computed when the patient provides answers in fewer than 6 categories. When the HAQ-DI is used to assess disability in a specific disease or condition, usually a single-word change is made in the stem to identify the condition<sup>13,66</sup>. Disability repeatedly has been correlated to mortality rates, progression of aging, and health care resource utilization<sup>25,57,135,181</sup>.

**2. Discomfort.** Pain is one of the most complex dimensions to measure, since it is a subjective composite of physiological, psychological, and social dimensions<sup>19</sup>. In the early years, the ARAMIS group conducted extensive testing to develop a valid pain measurement instrument and had attempted to elaborate pain activity by where the patient feels pain, when it occurs, and by its severity. However, this failed to yield an index that outperformed a simple VAS in terms of reliability, validity, and sensitivity to change<sup>55,135</sup>. As a result, the HAQ retains the basic tenet that “pain is what the patient says it is.” The HAQ Pain Scale consists of a double anchored horizontal VAS that is scored from zero (no pain) to 3 (severe pain) — or alternatively from 0 (no pain) to 100 (severe pain). The VAS for pain has been used widely in experimental, observational, and clinical settings<sup>17,89,94,119,135,164</sup>.

**3. Drug side effects.** Evaluation of drug therapy requires assessment of both effectiveness and toxicity. Toxicity data collected by the full HAQ include: the offending drug, dosage, time taking drug, specific side effects, degree of severity, the importance to the patient, and subsequent drug course, i.e., whether the drug was discontinued due to the side effect. Several publications have reported outcomes using HAQ drug side effect data<sup>135,152,154</sup>. In addition, HAQ-derived drug side effect data permitted the develop-

ment of a summary toxicity index (TI) that quantifies the magnitude of adverse effects (toxicity) associated with specific medications<sup>135,173</sup>. The TI is a first attempt to quantitatively describe the overall toxicity of medication; prior adverse effect assessments had used variables comprised of the percentage of patients discontinuing the drug because of side effects or had presented comparative frequencies of selected individual side effects. The TI comprises HAQ side effect data, laboratory abnormalities, and hospitalizations. To obtain the TI, standardized rules are applied to attribute particular events to particular therapies based on known toxicities of particular drugs as reported in the literature [e.g., a patient was hospitalized for gastrointestinal bleeding after taking nonsteroidal antiinflammatory drugs (NSAID)]. Weights established for different side effects, resulting from ratings by physicians, patients, and health professionals, are then assigned. The TI has been shown to be valid and sensitive for differing weights and found to be stable<sup>135,152</sup>. Since development of the TI, comparison of adverse events between NSAID has documented 2- to 4-fold differences in side effects, in contrast to conventional assumptions of their equivalence<sup>61</sup>, and TI scores of disease modifying antirheumatic drugs (DMARD) have been found to be variable and sometimes to be less toxic than NSAID<sup>62</sup>.

**4. Dollar costs.** Information for computing and adjusting direct medical costs and indirect costs due to loss of productivity are captured by the full HAQ. Direct cost data include physician visits, hospital days, laboratory costs, radiographs, medications, and other medical costs including use of alternative treatments and procedures. All major cost items such as hospitalizations, surgeries, and procedures are audited and source documentation obtained. Direct costs are measured in terms of units of service that are then assigned dollar values, allowing automatic adjustment for inflation and for different pricing structures in different regions. Standard costs for each service are developed from multiple sources (e.g., Physicians' Fee Reference, Medicare reimbursements, surveys of providers, insurance company data, American Hospital Association data, and pharmaceutical industry sources) and applied to computations that cumulate such variables as doctor visits, hospital days, and medication costs into a direct cost figure. While actual charges are sometimes used for validation, differences between costs and charges confound such data and decrease its overall utility. Indirect costs are derived from patient report of days lost from paid employment due to the patient's illness. A number of major studies have used HAQ cost data<sup>24,25,67,135,181</sup>.

**5. Death.** In this HAQ dimension, verification and cause of death are obtained by ARAMIS protocols that describe procedures for identifying deaths, time to death, and causes of death for patients lost to followup. The National Death Index is searched annually to identify whether patients lost to followup have died. A number of mortality studies have been published

using data from these sources and have included correlations with morbidity and costs<sup>108,135,181</sup>.

## GLOBAL HEALTH

Both the short and full HAQ contain the HAQ's patient Global Health Analog Scale. It is among the common VAS instruments that include the Torrance "feeling thermometer" in the EuroQol instrument and the VAS in the Arthritis Impact Measurement Scales (AIMS), which are used to measure quality of life. The HAQ Global is a 15 cm double anchored horizontal VAS that runs from zero, representing "very well," to 100, "very poor," and has been validated as a measure of quality of life<sup>22</sup>. Fries and Ramey<sup>55</sup> compared the HAQ Global to the Torrance quality-of-life "feeling thermometer" and found the 2 scales to be highly correlated ( $r = -0.676$ ,  $p < 0.001$ ), indicating that both instruments are measuring similar quality of life constructs.

## CORRELATIONS OF HAQ-DI WITH OTHER HEALTH STATUS MEASURES

The HAQ-DI has been significantly correlated with a wide variety of health status measures, including self-report measures, biochemical and clinical studies, assessment of morbidity, evaluation of health care resource utilization and cost estimations, and studies of mortality<sup>135</sup>. Among the self-report measures that have been correlated with the HAQ-DI since the review by Ramey and Fries in 1996 are the AIMS<sup>161</sup>, AIMS2<sup>9</sup>, global health status<sup>98,123</sup>, VAS pain scale<sup>98,165</sup>, Beck Depression Scale<sup>156</sup>, Carstairs Index<sup>109</sup>, Danish Nottingham Health Profile<sup>163</sup>, Disease Activity Score<sup>84,156,165</sup>, Dutch AIMS<sup>165</sup>, EuroQol<sup>22</sup>, Hollingshead Index<sup>105</sup>, Life Event Interview<sup>102</sup>, London Handicap Scale<sup>74</sup>, Nottingham Health Profile<sup>83</sup>, Medical Outcome Study Short Form-36 (SF-36)<sup>22,88,162</sup>, Social Network Delineation Questionnaire<sup>63</sup>, Trait Anxiety<sup>133</sup>, and the WOMAC<sup>22,136,179</sup>. Correlations with clinical measures have included the areas of joint and muscle activity<sup>27,33,82,98,105,119,123,126,156,159,165,176</sup>, bone health and radiographs<sup>27,53,92,155,161</sup>, body fat<sup>92,116,155</sup>, and health behaviors<sup>93,144</sup>. Biochemical assessments have included C-reactive protein<sup>31,89,177</sup> and human leukocyte antigen (HLA) typing<sup>76,141,146</sup>.

In addition, the HAQ-DI has been utilized as a predictor variable in investigations of productivity, morbidity, health care utilization, health care costs, and death. Functional status evaluated by the HAQ-DI has been significantly correlated with work related measures like work capacity, household work performance, work task performance, work disability, occupation, and ability to live independently<sup>13,49,66,90,128,135,157,175,178</sup>. In investigations related to health care, the HAQ-DI has been correlated with myriad assessments of health care such as direct costs<sup>25,135,153,183,184</sup>, hospital admissions, length of hospital stay, postsurgery delirium, use of aids and devices, health care resource utilization, health care system performance, in miscellaneous other areas like specialty care and patient satisfaction with

health care workers, in post-total knee replacement surgery, and predictors of mortality<sup>29,135,170,171</sup>.

### CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ)

The HAQ-DI was used as a template by Singh and colleagues<sup>151</sup> to develop the CHAQ, which is a parent and/or self-administered questionnaire designed to measure health status in children as young as one year of age. These investigators added several new questions and modified existing ones, so that for each functional area there is at least one question that is relevant to children of all ages. The CHAQ has been validated in patients with juvenile RA<sup>50,69,103,115</sup> and dermatomyositis<sup>45</sup>, and has been administered in studies of children with spina bifida<sup>5</sup>, polyarticular juvenile chronic arthritis<sup>140</sup>, juvenile arthritis<sup>174</sup>, and oligoarticular juvenile chronic arthritis<sup>142</sup>. Since its inception and the last HAQ review in 1995<sup>135</sup>, the CHAQ has continued to show excellent psychometric properties<sup>43,45,50,51,85,113,140,142,167,174</sup> and has been translated into more than a dozen languages (Table 2).

### LANGUAGE AND CULTURAL ADAPTATIONS

The HAQ-DI was originally developed and validated for

Table 2. Translations and cultural adaptations of the adult Health Assessment Questionnaire (HAQ) and the Childhood Health Assessment Questionnaire (CHAQ).

Independent translations and adaptations: Arabic<sup>149</sup>, Australian<sup>28,77</sup>, Austrian<sup>150</sup>, Austrian CHAQ<sup>97</sup>, Bulgarian CHAQ<sup>112</sup>, Chinese<sup>97</sup>, Croatian CHAQ<sup>73</sup>, Danish CHAQ<sup>117</sup>, Dutch CHAQ<sup>182</sup>, Czechoslovakian CHAQ<sup>32</sup>, English (British) CHAQ<sup>120</sup>, Finnish<sup>72</sup>, Finnish CHAQ<sup>127</sup>, Flemish CHAQ<sup>91</sup>, French (France)<sup>71</sup>, French CHAQ<sup>131</sup>, Georgian CHAQ<sup>125</sup>, German<sup>101</sup>, German CHAQ<sup>52</sup>, Greek CHAQ<sup>132</sup>, Hebrew CHAQ<sup>75</sup>, Hungarian CHAQ<sup>122</sup>, Italian<sup>137,145</sup>, Italian CHAQ<sup>44,143</sup>, Latvian CHAQ<sup>139</sup>, Korean<sup>11</sup>, Korean CHAQ<sup>12</sup>, The Netherlands<sup>78,79,166</sup>, Norwegian<sup>51,96</sup>, Norwegian CHAQ<sup>50,147</sup>, Polish<sup>138</sup>, Portuguese (Brazil)<sup>47,48</sup>, Portugal<sup>47</sup>, Portuguese CHAQ<sup>107,110</sup>, Russian CHAQ<sup>118</sup>, Scandinavian (multiple languages)<sup>20</sup>, Scottish<sup>100,129</sup>, Serbian CHAQ<sup>160</sup>, Slovak CHAQ<sup>168</sup>, Spanish (Mexico)<sup>23</sup>, Spanish<sup>42,68</sup>, Spanish CHAQ<sup>34</sup>, Chilean<sup>30,114</sup>, Costa Rican<sup>10,64,69,115</sup>, Argentinian<sup>115</sup>, Swedish<sup>7,15,16,21,35-41,158</sup>, Swedish CHAQ<sup>7,8,81</sup>, Swiss German and Swiss French<sup>174</sup>, Thai<sup>123</sup>, Turkish<sup>99,148</sup>, Turkish CHAQ<sup>124</sup>.

Translations/adaptations available through the Health Outcomes Group (E-mail: HOG\_USA@CompuServe.com): Australian, Austrian, Belgian Dutch (Flemish), Belgian French, Canadian French, Chinese (Cantonese, Hong Kong), Croatian, Danish, English (Canadian, United Kingdom), Finnish, French (France), German (Germany, Switzerland), Greek, Israel (English), Hebrew, Italian, Lithuanian, Portuguese (Brazil, Portugal), Romanian, Singapore (English, Malay, Mandarin), Slovenian, South Africa (Afrikaans, English), Spanish (Argentina, Chile, Colombia, Costa Rica, Guatemala, Peru, Spain, United States, Venezuela), Swedish, Turkish

Translations/adaptations available through the MAPI Institute (<http://www.mapi-research-inst.com>): Australian, Austrian (German), Belgian Dutch (Flemish), Belgian French (Walloon), Canadian French, Czech Republic, Danish, Dutch, English (Canadian, India, New Zealand, United Kingdom), Finnish, French (France), German, Greek, Hebrew, Hungarian, Israel, Italian, Japanese, Norwegian, Polish, Portuguese (Brazil), Russian, Slovak Republic, South Africa (Afrikaans, English), Spanish (Argentina, Costa Rica, Guatemala, Mexico, Spain, Venezuela), Swedish

English speaking populations in the United States and Canada, and has since been translated or culturally adapted into more than 60 different languages or dialects, often with only minor changes. Table 2 lists translations for HAQ-DI since the last review<sup>135</sup> and includes translations for the CHAQ. Translations and cultural adaptations of the HAQ-DI are usually carried out by administering investigators. Many have also been performed by the MAPI Research Institute in Lyon, France, and the Health Outcomes Group in Palo Alto, California, both of which have had extensive experience in translating and culturally validating the HAQ-DI; fees are sometimes charged by these vendors.

Translated HAQ-DI have generally been fully validated, using methods such as test-retest reliability, item-total correlations, convergent validity, interviewer versus self-administered formats, and factor analyses. To date, culturally adapted HAQ-DI instruments have proved to be as reliable and valid as their parent. To adapt the HAQ-DI culturally, modifications of individual items have sometimes been necessary. The types of items most frequently in need of adaptation have included colloquial expressions or those for which names or types of items or utensils are culturally idiosyncratic. For example, some Asian cultures do not consume milk in cartons; thus, an appropriate substitution in keeping with the original intent of the item is made. In some European countries a bathtub is much more commonly used than a shower, requiring question modification.

### CONCEPTUAL ISSUES IN MEASUREMENT

The importance of assessing health outcomes in chronic disease has become recognized and appreciated and is a significant component of study design. As a result, there has been escalating interest in issues regarding measurement properties and instrument development.

*Generic versus disease-specific instruments.* A “generic” (suitable for many diseases and conditions) or a “disease-specific” (limited to use in one or a few disease conditions) distinction has been made for several instruments in assessing patient outcomes. For example, the WOMAC and AIMS were designed for and are correctly labeled as disease-specific assessment tools for OA and arthritis, respectively<sup>14,185</sup>. They have not been used in other conditions. The SF-36<sup>172</sup> has long been established as a generic instrument for measuring dimensions of patient outcomes in numerous types of conditions. Because the full HAQ originated from the rheumatology field, it sometimes has been characterized as a disease-specific instrument rather than having been adjudicated on the basis of its structure, content, and history of use. The HAQ has been and can be administered across diverse disciplines and in different cultures. The “5 Ds” of disability, discomfort, drug toxicity, dollars, and death are generic.

The HAQ has proved itself as a generic tool from its generic, largely universal patient centered foundations and its numerous demonstrated applications in a variety of popula-

tions, ranging from normal populations to aging populations to patients with HIV-AIDS, as well as in children and adults with diverse rheumatic conditions. Functional sections of other generic instruments, such as the SF-36 and the Sickness Impact Profile, have been significantly correlated with the HAQ-DI and measure similar constructs<sup>15,22,78,88,162</sup>, although the HAQ also includes additional items that assess dollar costs, drug side effects, and death that are not part of these instruments. None of these instruments, including the HAQ, is entirely complete, and there does not appear to exist an instrument that can be considered the “ideal” generic instrument: supplementary questions or instruments will probably always be required for some specific studies.

*Floor and ceiling effects.* Some investigators have suggested that many outcome instruments, including the HAQ-DI, are not sensitive to change at the ends of the spectrum, e.g., a person with a HAQ-DI of zero (not disabled) cannot get better, while the individual could perhaps become more fit, and a person with a HAQ-DI of 3 (completely disabled) seemingly cannot become more disabled, although perhaps the patient could worsen. However, this issue can be interpreted alternatively. If 10% of a sample of patients with RA have a HAQ-DI score of zero, this may not be a “ceiling effect.” It can instead be interpreted to mean that if 10% of patients report no difficulties with any of their activities of daily living, then 10% of patients with RA have no disability. That none of these patients might be able to run a mile in 8 minutes is neither relevant nor useful to estimation of their level of disability. If we proposed a “fitness” index, the index would have to accurately represent “fitness.” A disability index must represent disability. If a patient is completely unable to perform any activity of daily living and has a HAQ-DI score of 3, then they are in essence totally disabled. In the disability context, you cannot be more than totally disabled, although as a patient you might get worse in other areas, such as pain and cognition. Normal, healthy individuals consistently score zero on the HAQ-DI. In our view, this is not a ceiling effect; it is a characterization of the disability status of the patient. In this sense, “floor” and “ceiling” effects define the limits of the concept of disability and may be considered a strength and not a weakness.

*Distances between values.* The comparison of outcomes relative to differences in scores at different ranges on a scale is a significant issue. For example, the HAQ-DI has category ranks for each variable, where zero equals “without any difficulty,” 1 “with some difficulty,” 2 “with much disability,” and 3 represents “unable to do.” The question is whether we know if the “disability distance” between zero and 1 is the same as between 1 and 2 or between 2 and 3. This is a provocative question, to which the answer is probably “no,” and one that is being studied. In practice, the problem is less than might be expected, since most patients progress irregularly across the HAQ-DI’s 8 categories, averaging out distance effects, if any. Thus, the HAQ-DI appears to behave smoothly over time,

with progression rates and treatment effects reasonably similar regardless of initial HAQ-DI level.

*Proliferation of instruments.* In recent years there has been introduction of several new assessment tools that conceptually or in content are similar to established instruments. The best studied and most widely used instruments share several criteria: they are based on a coherent conceptual model; they have demonstrated reliability, validity, and sensitivity to change; they have been widely used in diverse settings and have good norms; they are available in multiple languages and have been stable for a sufficient length of time that longitudinal studies are possible. Although no existing instrument is ideal, and a new instrument might contain improvements, if the improvements are not substantial, the instrument will not likely make an enduring contribution. Lack of multiple validations and assessments and difficulty in relating results to the literature are disadvantages. Given their histories, we believe that the HAQ, which has evolved de facto into the standard instrument in many areas, and the SF-36 (or SF-12), which has the largest overall use and a long history, are viable choices for use as standard instruments, with additional question sets added to meet the needs of particular studies. We must be able to compare results across studies and across diseases, and this cannot occur without an essentially common vocabulary. A few standard instruments, meeting the above criteria, and to which disease-specific questions may be added as required would appear to have substantial advantages over a proliferation of additional variations on a theme.

## CONCLUSIONS

A full understanding of the natural history of disease or clinical treatment requires consideration of a comprehensive set of patient centered health outcome variables that are collected longitudinally. Outcome measurement is rapidly increasing in use, and we anticipate increased focus on a smaller number of instruments with supplemental questions used for disease or study-specific queries. Such instruments will have extensive validations and good psychometric properties, and will be available in many languages. We believe the HAQ has appropriate attributes to be among those considered for use as standard instruments. New applications may be to guide use of therapeutic choices and as justification for the use of powerful, but expensive, new therapeutic agents.

Collection of longitudinal patient outcome data, based on the 5 patient centered dimensions, is increasingly standard in clinical trials, epidemiologic studies, and in patient care, representing a major paradigm shift over the past 2 decades. The HAQ has increased the credibility and use of comprehensive measurement techniques involving validated patient self-report and has led to a new appreciation of outcome assessment. We hope that this review of the Health Assessment Questionnaire will prove useful as a guide to the literature and to understanding pertinent issues regarding patient outcome assessment.



## REFERENCES

1. Donabedian A. Promoting quality through evaluating the process of patient care. *Med Care* 1968;6:181-202.
2. Katz S, Ford A, Moskowitz R, Jackson B, Jaffe M. Studies of illness in the aged: the index of ADL — a standardized measure of biological and psychosocial function. *JAMA* 1963;185:914-9.
3. Steinbrocker O, Traeger C, Batterman R. Therapeutic criteria in rheumatoid arthritis. *JAMA* 1949;140:659-62.
4. Convery F, Minter M, Amiel D, Conneti K. Polyarticular disability: a functional assessment. *Arch Phys Med Rehabil* 1977;58:494-9.
5. Alman B, Bhandari M, Wright J. Function of dislocated hips in children with lower level spina bifida. *J Bone Joint Surg Br* 1996;78:294-8.
6. Anderson KO, Bradley LA, McDaniel LK, et al. The assessment of pain in rheumatoid arthritis: disease differentiation and temporal stability of a behavioral observation method. *J Rheumatol* 1987;14:700-4.
7. Andersson Gare B, Fasth A, Wiklund I. Measurement of functional status in juvenile chronic arthritis: evaluation of a Swedish version of the Childhood Health Assessment Questionnaire. *Clin Exp Rheumatol* 1993;11:569-76.
8. Andersson Gare B, Ruperto N, Berg S, et al. The Swedish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S146-50.
9. Archenholtz B, Bjelle A. Reliability, validity, and sensitivity of a Swedish version of the revised and expanded Arthritis Impact Measurement Scales (AIMS2). *J Rheumatol* 1997;24:1370-7.
10. Arguedas O, Andersson-Gare B, Fasth A, Porras O. Development of a Costa Rican version of the Childhood Health Assessment Questionnaire. *J Rheumatol* 1997;24:2233-41.
11. Bae SC, Cook EF, Kim SY. Psychometric evaluation of a Korean Health Assessment Questionnaire for clinical research. *J Rheumatol* 1998;25:1975-9.
12. Bae SC, Ruperto N, Lee JH, Uhm WS, Park YW, Kim SY. The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S96-100.
13. Barrett EM, Scott DG, Wiles NJ, Symmons DP. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. *Rheumatology* 2000; 39:1403-9.
14. Bellamy N. WOMAC Osteoarthritis Index: A user's guide. London, ON: University of Western Ontario; 1996.
15. Bendtsen P, Bjurulf P. Perceived needs and patient satisfaction in relation to care provided in individuals with rheumatoid arthritis. *Qual Assur Health Care* 1993;5:243-53.
16. Bendtsen P, Hornquist JO. Severity of rheumatoid arthritis, function and quality of life: sub-group comparisons. *Clin Exp Rheumatol* 1993;11:495-502.
17. Berkanovic E, Oster P, Wong WK, et al. The relationship between socioeconomic status and recently diagnosed rheumatoid arthritis. *Arthritis Care Res* 1996;9:257-62.
18. Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. *J Rheumatol* 1994;21 Suppl 41:86-9.
19. Bonica J. The management of pain. Philadelphia: Lea & Febiger; 1990.
20. Borg G, Allander E, Lund B, et al. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2 year, double blind, placebo controlled study. *J Rheumatol* 1988;15:1747-54.
21. Bostrom C, Harms-Ringdahl K, Nordemar R. Clinical reliability of shoulder function assessment in patients with rheumatoid arthritis. *Scand J Rheumatol* 1991;20:36-48.
22. Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML. Generic and condition-specific outcome measures for people with osteoarthritis of the knee. *Rheumatology* 1999;38:870-7.
23. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D. How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). *Clin Exp Rheumatol* 1993;11:117-21.
24. Clarke AE, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. *J Rheumatol* 1997;24:1051-60.
25. Clarke AE, Levinton C, Joseph L, et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. *J Rheumatol* 1999;26:1068-75.
26. Clements PJ, Wong WK, Hurwitz EL, et al. Correlates of the disability index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. *Arthritis Rheum* 1999;42:2372-80.
27. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. *Arthritis Rheum* 2000;43:2445-54.
28. Crotty M, McFarlane AC, Brooks PM, Hopper JL, Bieri D, Taylor SJ. The psychosocial and clinical status of younger women with early rheumatoid arthritis: a longitudinal study with frequent measures. *Br J Rheumatol* 1994;33:754-60.
29. Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients about total knee replacement. *J Bone Joint Surg Br* 1998;80:63-9.
30. De Inocencio J, Garcia-Consuegra J, Merino R, Calvo I, Garcia JJ, Ruperto N. The European Spanish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S141-5.
31. Devlin J, Gough A, Huissoon A, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. *J Rheumatol* 1997;24:9-13.
32. Dolezalova P, Ruperto N, Nemcova D, Blichova M, Hoza J. The Czech version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S45-S49.
33. Drossaers-Bakker KW, Kroon HM, Zwinderman AH, Breedveld FC, Hazes JM. Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function. *Rheumatology* 2000;39:998-1003.
34. Duarte C, Ruperto N, Goyochea M, et al. The Mexican version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S106-S110.
35. Eberhardt KB, Svensson B, Mortiz U. Functional assessment of early rheumatoid arthritis. *Br J Rheumatol* 1988;27:364-71.
36. Eberhardt KB, Rydgren LC, Pettersson H, Wollheim FA. Early rheumatoid arthritis — onset, course, and outcome over 2 years. *Rheumatol Int* 1990;10:135-42.
37. Eberhardt K, Larsson BM, Nived K. Psychological reactions in patients with early rheumatoid arthritis. *Patient Educ Couns* 1993;20:93-100.
38. Eberhardt K, Larsson BM, Nived K. Early rheumatoid arthritis — some social, economical, and psychological aspects. *Scand J Rheumatol* 1993;22:119-23.
39. Eberhardt K, Grubb R, Johnson U, Pettersson H. HLA-DR

- antigens, Gm allotypes and anti-allotypes in early rheumatoid arthritis — their relation to disease progression. *J Rheumatol* 1993;20:1825-9.
40. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. *Scand J Rheumatol* 1988;17:263-71.
  41. Ekdahl C. Muscle function in rheumatoid arthritis. Assessment and training. *Scand J Rheumatol* 1990;86 Suppl:9-61.
  42. Esteve-Vives J, Batlle-Gualda E, Reig A. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. *J Rheumatol* 1993;20:2116-22.
  43. Fan J, Wessel J, Ellsworth J. The relationship between strength and function in females with juvenile rheumatoid arthritis. *J Rheumatol* 1998;25:1399-405.
  44. Fantini F, Corvaglia G, Bergomi P, et al. Validation of the Italian version of the Stanford Childhood Health Assessment Questionnaire for measuring functional status in children with chronic arthritis. *Clin Exp Rheumatol* 1995;13:785-91.
  45. Feldman B, Ayling-Campos A, Luy L, Stevens D, Silverman E, Laxer R. Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. *J Rheumatol* 1995;22:326-31.
  46. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *Arthritis Rheum* 1993;36:729-40.
  47. Ferraz MB, Oliveira LM, Araujo PM, Atra E, Tugwell P. Crosscultural reliability of the physical ability dimension of the Health Assessment Questionnaire. *J Rheumatol* 1990;17:813-7.
  48. Ferraz MB, Oliveira LM, Araujo PM, Atra E, Walter SD. EPM-ROM Scale: an evaluative instrument to be used in rheumatoid arthritis trials. *Clin Exp Rheumatol* 1990;8:491-4.
  49. Fex E, Larsson BM, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. *J Rheumatol* 1998;25:44-50.
  50. Flato B, Aasland A, Vinje O, Forre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthritis. *J Rheumatol* 1998;25:366-75.
  51. Flato B, Sorskaar D, Vinje O, et al. Measuring disability in early juvenile rheumatoid arthritis: evaluation of a Norwegian version of the Childhood Health Assessment Questionnaire. *J Rheumatol* 1998;25:1851-8.
  52. Foeldvari I, Ruperto N, Dressler F, et al. The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S71-S75.
  53. Frediani B, Allegri A, Falsetti P, et al. Bone mineral density in patients with psoriatic arthritis. *J Rheumatol* 2001;28:138-43.
  54. Fries J, Ramey D. Platonic outcomes. *J Rheumatol* 1993;20:415-7.
  55. Fries JF, Ramey DR. "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis. *J Rheumatol* 1997;24:1697-702.
  56. Fries JF, Singh G, Morfeld D, Hubert HB, Lane NE, Brown BW Jr. Running and the development of disability with age. *Ann Intern Med* 1994;121:502-9.
  57. Fries JF, Singh G, Morfeld D, O'Driscoll P, Hubert H. Relationship of running to musculoskeletal pain with age. A six-year longitudinal study. *Arthritis Rheum* 1996;39:64-72.
  58. Fries J, Spitz P, Kraines R, Holman H. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
  59. Fries J, Spitz P, Young D. The dimensions of health outcomes: the Health Assessment Questionnaire. *J Rheumatol* 1982;9:789-93.
  60. Fries J, Spitz P. The hierarchy of patient outcomes. In: Spilker B, editor. *Quality of life assessment for clinical trials*. New York: Raven Press; 1990.
  61. Fries J, Williams C, Bloch D. The relative toxicity of nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 1991;34:1353-60.
  62. Fries J, Williams C, Ramey D, Bloch D. The relative toxicity of disease-modifying antirheumatic drugs. *Arthritis Rheum* 1993;36:297-306.
  63. Fyrand L, Moum T, Wichstrom L, Finset A, Glennas A. Social network size of female patients with rheumatoid arthritis compared to healthy controls. *Scand J Rheumatol* 2000;29:38-43.
  64. Garcia-Garcia J, Gonzalez-Pascual E, Pou-Fernandez J, Sinigh G, Jimenez R. Development of a Spanish (Castilian) version of the Childhood Health Assessment Questionnaire. Measurement of health status in children with juvenile chronic arthritis. *Clin Exp Rheumatol* 2000;18:95-102.
  65. Gill DL, Kelley BC, Williams K, Martin JJ. The relationship of self-efficacy and perceived well-being to physical activity and stair climbing in older adults. *Res Q Exerc Sport* 1994;65:367-71.
  66. Gillen M. Injuries from construction falls. Functional limitations and return to work. *AAOHN J* 1999;47:65-73.
  67. Gironimi G, Clarke AE, Hamilton VH, et al. Why health care costs more in the US: comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. *Arthritis Rheum* 1996;39:979-87.
  68. Gonzalez VM, Stewart A, Ritter PL, Lorig K. Translation and validation of arthritis outcome measures into Spanish. *Arthritis Rheum* 1995;38:1429-46.
  69. Goycochea-Robles M, Garduno-Espinosa J, Vilchis-Guizar E, Ortiz-Alvarez O, Burgos-Vargas R. Validation of a Spanish version of the Childhood Health Assessment Questionnaire. *J Rheumatol* 1997;24:2242-5.
  70. Green LW. *Measurement and evaluation in health education and health promotion*. Palo Alto: Mayfield Publishing; 1986.
  71. Guillemin F, Braincon S, Pourel J. Measurement of the functional capacity in rheumatoid polyarthritis: a French adaptation of the Health Assessment Questionnaire (HAQ) [in French]. *Rev Rhum Mal Osteoartic* 1991;58:459-65.
  72. Hakala M, Nieminen P, Manelius J. Joint impairment is strongly correlated with disability measured by self-report questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population based series. *J Rheumatol* 1994;21:64-9.
  73. Harjacek M, Ruperto N, Ostojic J, Bukovac LT. The Croatian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S40-4.
  74. Harwood RH, Carr AJ, Thompson PW, Ebrahim S. Handicap in inflammatory arthritis. *Br J Rheumatol* 1996;35:891-7.
  75. Hashkes P, Uziel Y, Press J, et al. The Hebrew version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S86-90.
  76. Hedger SC, Macardle P, Bond MJ, Ahern MJ, Smith MD, Roberts-Thomson PJ. Shared rheumatoid epitope as a risk factor in determining outcome in rheumatoid arthritis. *Aust NZ J Med* 1999;29:234-8.
  77. Heytman M, Ahern MJ, Smith MD, Roberts-Thomson PJ. The longterm effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. *J Rheumatol* 1994;21:435-41.
  78. Hidding A, de Witte L, van der Linden S. Determinants of self-reported health status in ankylosing spondylitis. *J Rheumatol* 1994;21:275-8.
  79. Hidding A, van der Linden S, Gielen X, de Witte L, Dijkmans B, Moolenburgh D. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. *Arthritis Care Res* 1994;7:90-6.
  80. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F.

- The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. *Arthritis Rheum* 1992;35:498-502.
81. Hofer M, Ruperto N, Sauremann R, et al. The Swiss German and Swiss French versions of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S151-S157.
  82. Houssien DA, Choy EH, Carr AJ, Scott DL. Rheumatoid arthritis outcome in routine practice: a comparison of outcome assessments [abstract]. *Arthritis Rheum* 1997;40 Suppl:S152.
  83. Houssien DA, McKenna SP, Scott DL. The Nottingham Health Profile as a measure of disease activity and outcome in rheumatoid arthritis. *Br J Rheumatol* 1997;36:69-73.
  84. Houssien DA, Stucki G, Scott DL. A patient-derived disease activity score can substitute for a physician-derived disease activity score in clinical research. *Rheumatology* 1999;38:48-52.
  85. Huber A, Lang B, LeBlanc C, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. *Arthritis Rheum* 2000;43:541-9.
  86. Hubert H, Bloch D, Fries J. Risk factors for physical disability in an aging cohort: the NHANES I epidemiologic followup study. *J Rheumatol* 1993;20:480-8.
  87. Huemer C, Ruperto N, Huemer M, et al. The Austrian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S15-S19.
  88. Husted JA, Gladman DD, Cook RJ, Farewell VT. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. *J Rheumatol* 1998;25:2146-55.
  89. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA. Predictors of functional status in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2000;59:223-6.
  90. Jantti J, Aho K, Kaarela K, Kautiainen H. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. *Rheumatology* 1999;38:1138-41.
  91. Joos R, Ruperto N, Wouters C, et al. The Belgian-Flemish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S20-4.
  92. Jordan JM, Luta G, Renner JB, et al. Self-reported functional status in osteoarthritis of the knee in a rural southern community: the role of sociodemographic factors, obesity, and knee pain. *Arthritis Care Res* 1996;9:273-8.
  93. Jordan JM, Luta G, Renner JB, Dragomir A, Hochberg MC, Fryer JG. Ethnic differences in self-reported functional status in the rural south: the Johnston County Osteoarthritis Project. *Arthritis Care Res* 1996;9:483-91.
  94. Kandziora F, Mittlmeier T, Kerschbaumer F. Stage-related surgery for cervical spine instability in rheumatoid arthritis. *Eur Spine J* 1999;8:371-81.
  95. Kind P. The EuroQol Instrument: An index of health-related quality of life. In: Spilker B, editor. *Pharmacoeconomics and quality of life clinical trials*. Philadelphia: Lippincott-Raven; 1996:191-201.
  96. Kjeldsen-Kragh J, Haugen M, Borchgrevink CF, et al. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. *Lancet* 1991;338:899-902.
  97. Koh ET, Seow A, Pong LY, et al. Cross cultural adaptation and validation of the Chinese Health Assessment Questionnaire for use in rheumatoid arthritis. *J Rheumatol* 1998;25:1705-8.
  98. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. *Arthritis Rheum* 2000;43:1478-87.
  99. Kucukdeveci AA, McKenna SP, Kutlay S, Gursel Y, Whalley D, Arasil T. The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. *Int J Rehabil Res* 2000;23:31-8.
  100. Lambert CM, Hurst NP, Lochhead A, McGregor K, Hunter M, Forbes J. A pilot study of the economic cost and clinical outcome of day patient vs inpatient management of active rheumatoid arthritis. *Br J Rheumatol* 1994;33:383-8.
  101. Lautenschlager J, Mau W, Kohlmann T, et al. Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire [in German]. *Z Rheumatol* 1997;56:144-55.
  102. Leymarie F, Jolly D, Sanderman R, et al. Life events and disability in rheumatoid arthritis: a European cohort. *Br J Rheumatol* 1997;36:1106-12.
  103. Len C, Goldenberg J, Ferraz MB, Hilario MO, Oliveira LM, Sacchetti S. Crosscultural reliability of the Childhood Health Assessment Questionnaire. *J Rheumatol* 1994;21:2349-52.
  104. Lorig KR, Cox T, Cuevas Y, Kraines RG, Britton MC. Converging and diverging beliefs about arthritis: Caucasian patients, Spanish speaking patients, and physicians. *J Rheumatol* 1984;11:76-9.
  105. Lotstein DS, Ward MM, Bush TM, Lambert RE, van Vollenhoven R, Neuwelt CM. Socioeconomic status and health in women with systemic lupus erythematosus. *J Rheumatol* 1998;25:1720-9.
  106. Lubeck DP, Fries JF. Assessment of quality of life in early stage HIV-infected persons: data from the AIDS Time-oriented Health Outcome Study (ATHOS). *Qual Life Res* 1997;6:494-506.
  107. Machado CS, Ruperto N, Silva CH, et al. The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S25-9.
  108. Matsuda Y, Wang BWE, Williamson CI, Fries JF, Singh G. Mortality of rheumatoid arthritis in a contemporary cohort: Analysis of 918 deaths in 4628 patients (25,814 person-years) [abstract]. *Arthritis Rheum* 2000;43 Suppl:S183.
  109. McEntegart A, Morrison E, Capell HA, et al. Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. *Ann Rheum Dis* 1997;56:410-3.
  110. Melo-Gomes JA, Ruperto N, Canhao H, et al. The Portuguese version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S126-30.
  111. Meenan RF, Gertman PM, Mason JH, Dunaif R. The Arthritis Impact Measurement Scales. Further investigations of a health status measure. *Arthritis Rheum* 1982;25:1048-53.
  112. Mihaylova D, Ruperto N, Kibarova V, et al. The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S30-S34.
  113. Miller M, Dress A, Berry C. Decreased physical function in juvenile rheumatoid arthritis. *Arthritis Care Res* 1999;12:309-13.
  114. Miranda M, Ruperto N, Toso M, et al. The Chilean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S35-S39.
  115. Moroldo M, Cunto CD, Hubscher O, et al. Cross cultural adaptation and validation of an Argentine Spanish Version of the Stanford Childhood Health Assessment Questionnaire. *Arthritis Care Res* 1998;11:382-91.
  116. Munro R, Capell H. Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. *Ann Rheum Dis* 1997;56:326-9.
  117. Nielsen S, Ruperto N, Herlin T, Pedersen FK. The Danish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol*

- 2001;19 Suppl 23:S50-S54.
118. Nikishina I, Ruperto N, Kuzmina N, et al. The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S131-S135.
  119. Nordenskiöld U, Grimby G. Assessments of disability in women with rheumatoid arthritis in relation to grip force and pain. *Disabil Rehabil* 1997;19:13-9.
  120. Nugent J, Ruperto N, Grainger J, et al. The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S163-7.
  121. OMERACT. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Maastricht: April 29-May 3, 1992. *J Rheumatol* 1993;20:527-91.
  122. Orban I, Ruperto N, Balogh Z. The Hungarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S81-5.
  123. Osiri M, Deesomchok U, Tugwell P. Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the Health Assessment Questionnaire. *Rheumatology* 2001;40:555-8.
  124. Ozdogan H, Ruperto N, Kasapcopur O, et al. The Turkish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S158-62.
  125. Pagava K, Ruperto N, Shalamberidze L, Mshvidobadze N. The Georgian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S66-70.
  126. Paulus HE, Bulpitt KJ, Ramos B, Park G, Wong WK. Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis. *Arthritis Rheum* 2000;43:2743-50.
  127. Pelkonen P, Ruperto N, Honkanen V, Hannula S, Savolainen A, Lahdenne P. The Finnish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S55-9.
  128. Pincus T, Brooks R, Callahan L. Prediction of longterm mortality in patients with rheumatoid arthritis. *Ann Intern Med* 1994;120:26-34.
  129. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis — no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. *J Rheumatol* 1993;20:645-9.
  130. Potts M, Mazza S, Brandt K. Views of patients and physicians regarding the importance of various aspects of arthritis treatment correlations with health status and patient satisfaction. *Pt Ed Counsel* 1986;8:125-34.
  131. Pouchot J, Ruperto N, Lemelle I, et al. The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S60-S65.
  132. Pratsidou-Gertsis P, Vougiouka O, Tsitsami E, Ruperto N, Siampiloulou-Mavridou A. The Greek version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S76-S80.
  133. Radanov BP, Schwarz HA, Frost SA, Augustiny KF. Relationship between self-rated functional status and psychosocial stress in patients suffering from rheumatoid arthritis. *Psychother Psychosom* 1997;66:252-7.
  134. Ramey D, Raynauld J, Fries J. The Health Assessment Questionnaire 1992: status and review. *Arthritis Care Res* 1992;5:119-29.
  135. Ramey D, Fries J, Singh G. The Health Assessment Questionnaire 1995 — status and review. In: Spilker B, editor. *Quality of life and pharmacoeconomics in clinical trials*. 2nd ed. Philadelphia: Lippincott-Raven; 1996:227-37.
  136. Ramsey D, Fries J, Singh G, Lane N. Outcome assessment in osteoarthritis (OA): WOMAC or HAQ? [abstract]. *Arthritis Rheum* 1998;41 Suppl:S223.
  137. Ranza R, Marchesoni A, Calori G, et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. *Clin Exp Rheumatol* 1993;11:123-8.
  138. Romicka A, Ruperto N, Gutowska-Grzegorzczak G, Musiej-Nowakowska E, Wyszynska E. The Polish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S121-S125.
  139. Rumba I, Ruperto N, Bikis E, et al. The Latvian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S101-S105.
  140. Ruperto N, Levinson JE, Ravelli A, et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. *J Rheumatol* 1997;24:945-51.
  141. Ruperto N, Ravelli A, Levinson JE, et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. *J Rheumatol* 1997;24:952-8.
  142. Ruperto N, Ravella A, Migliavacca D, et al. Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis. *J Rheumatol* 1999;26:1827-30.
  143. Ruperto N, Ravelli A, Pistorio A, et al. The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S91-5.
  144. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. *Arthritis Rheum* 1996;39:1711-9.
  145. Salaffi F, Ferraccioli GF, Carotti M, Blasetti P, Cervini C. Disability in rheumatoid arthritis: the predictive value of age and depression [in Italian]. *Recenti Prog Med* 1992;83:675-9.
  146. Seidl C, Koch U, Buhleier T, et al. Association of (Q)R/KRAA positive HLA-DRB1 alleles with disease progression in early active and severe rheumatoid arthritis. *J Rheumatol* 1999;26:773-6.
  147. Selvaag A, Ruperto N, Asplin L, et al. The Norwegian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S116-S120.
  148. Senerdem N, Gul A, Konice M, et al. The use of two different Health Assessment Questionnaires in Turkish rheumatoid arthritis population and assessment of the associations with disability. *Clin Rheumatol* 1999;18:33-7.
  149. Shehab D, al-Jarallah K, Moussa MA. Validation of the Arabic version of the Health Assessment Questionnaire (HAQ) in patients with rheumatoid arthritis. *Rev Rhum Engl Ed* 1998;65:387-92.
  150. Singer F, Kolarz G, Mayrhofer F, Scherak O, Thumb N. The use of questionnaires in the evaluation of the functional capacity in rheumatoid arthritis. *Clin Rheumatol* 1982;1:251-61.
  151. Singh G, Athreya B, Fries J, Goldsmith D. Measurement of health status in children with juvenile rheumatoid arthritis. *Arthritis Rheum* 1994;37:1761-9.
  152. Singh G, Ramey DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. *Pharmacol Ther*

- 1994;62:175-91.
153. Singh G, Ramey D, Terry R, Wolfe F, Fries J. Costs of medical care for patients with osteoarthritis and rheumatoid arthritis: A 13 year study [abstract]. *Arthritis Rheum* 1996;39 Suppl:S71.
  154. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective — 1997. *J Rheumatol* 1998;25 Suppl 51:8-16.
  155. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. *J Rheumatol* 2000;27:2582-9.
  156. Sokka T, Kankainen A, Hannonen P. Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. *Arthritis Rheum* 2000;43:386-9.
  157. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. *Arthritis Rheum* 1997;40:1984-91.
  158. Stenstrom CH. Home exercise in rheumatoid arthritis functional class II: goal setting versus pain attention. *J Rheumatol* 1994;21:627-34.
  159. Stucki G, Bruhlmann P, Stucki S, Michel BA. Isometric muscle strength is an indicator of self-reported physical functional disability in patients with rheumatoid arthritis. *Br J Rheumatol* 1998;37:643-8.
  160. Susic G, Ruperto N, Stojanovic R, et al. The Serbian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S168-S172.
  161. Taccari E, Spadaro A, Rinaldi T, Riccieri V, Sensi F. Comparison of the Health Assessment Questionnaire and Arthritis Impact Measurement Scale in patients with psoriatic arthritis. *Rev Rhum Engl Ed* 1998;65:751-8.
  162. Talamo J, Frater A, Gallivan S, Young A. Use of the Short Form 36 (SF36) for health status measurement in rheumatoid arthritis. *Br J Rheumatol* 1997;36:463-9.
  163. Thorsen H, Hansen TM, McKenna SP, Sorensen SF, Whalley D. Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RAQoL). *Scand J Rheumatol* 2001;30:103-9.
  164. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. *J Rheumatol* 2000;27:623-9.
  165. van den Ende CH, Breedveld FC, Dijkmans BA, Hazes JM. The limited value of the Health Assessment Questionnaire as an outcome measure in short term exercise trials. *J Rheumatol* 1997;24:1972-7.
  166. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. *J Rheumatol* 1994;21:425-9.
  167. van der Net J, Prakken AB, Helders PJ, et al. Correlates of disablement in polyarticular juvenile chronic arthritis — a cross-sectional study. *Br J Rheumatol* 1996;35:91-100.
  168. Vesely R, Ruperto N, Vargova V, et al. The Slovak version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S136-S140.
  169. Wang BWE, Fries FJ. Area under the curve as a model of cumulative disability in rheumatoid arthritis [abstract]. *Arthritis Rheum* 1999;42 Suppl:S219.
  170. Ward MM, Lubeck D, Leigh JP. Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings. *J Rheumatol* 1998;25:641-9.
  171. Ward MM. Rheumatology visit frequency and changes in functional disability and pain in patients with rheumatoid arthritis. *J Rheumatol* 1997;24:35-42.
  172. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473-83.
  173. Welch V, Singh G, Strand V, et al. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index. *J Rheumatol* 2001;28:1188-91.
  174. Wessel J, Kaup C, Fan J, et al. Isometric strength measurements in children with arthritis: reliability and relation to function. *Arthritis Care Res* 1999;12:238-46.
  175. Westhoff G, Listing J, Zink A. Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care. *Arthritis Care Res* 2000;13:11-22.
  176. Wiles N, Dunn G, Barrett E, Silman A, Symmons D. Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis: a longitudinal analysis using generalized estimating equations. *J Clin Epidemiol* 2000;53:988-96.
  177. Wolfe F, Goldberg R. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. *J Rheumatol* 1997;24:1486-8.
  178. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. *J Rheumatol* 1998;25:2108-17.
  179. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. *Rheumatology* 1999;38:355-61.
  180. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2491 rheumatoid arthritis patients following leflunomide initiation. *J Rheumatol* 2001;28:982-9.
  181. Wong J, Ramey D, Singh G. Morbidity, mortality, and economics of rheumatoid arthritis [abstract]. *Arthritis Rheum* 2000;43 Suppl:S389.
  182. Wulffraat N, van der Net JJ, Ruperto N, et al. The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19 Suppl 23:S111-5.
  183. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. *Arthritis Rheum* 1999;42:1209-18.
  184. Clarke A, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A 12 year study. *J Rheumatol* 1997;24:1051-60.
  185. Meenan RF. The AIMS approach to health status measurement: conceptual background and measurement properties. *J Rheumatol* 1982;9:785-8.